The efficacy of Vitamin D3 on seizure attacks in the patients with drug-resistant epilepsy
Phase 3
Completed
- Conditions
- drug-resistant epilepsy.Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticusG40.211
- Registration Number
- IRCT20130730014217N2
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
drug-resistant epilepsy to treatment
No other disease
Vitamin D3 deficiency
Adult population over 18 years.
Exclusion Criteria
Patient's unwillingness and conscious dissatisfaction
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of seizures. Timepoint: At beginning and 1, 2 and 3 months after treatment, patients were visited and the number and duration of seizures occurred. Method of measurement: Blood test and evaluation of 25OH vitamin D.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Vitamin D3 receptor activation to seizure reduction in drug-resistant epilepsy (G40.211)?
How does Vitamin D3 supplementation compare to standard antiepileptic drugs in managing focal seizures with status epilepticus?
Which biomarkers correlate with response to Vitamin D3 in patients with intractable localization-related epilepsy (G40.211)?
What are the potential adverse effects of high-dose Vitamin D3 in drug-resistant epilepsy trials and mitigation strategies?
Are there synergistic effects of combining Vitamin D3 with ketogenic diet or other adjunct therapies for focal epileptic syndromes (G40.211)?